Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
Savara Inc. is evolving from a single-asset biotech company to a broader rare disease commercial infrastructure. The company is focusing on its drug MOLBREEVI, which targets autoimmune pulmonary alveolar proteinosis (PAP). With significant liquidity and regulatory momentum, Savara is well-positioned for future growth.
- ▪Savara is transitioning to a rare disease commercial infrastructure with its drug MOLBREEVI.
- ▪The company has a cash runway extending into the second half of 2027, supported by $203 million in liquidity.
- ▪MOLBREEVI has received Priority Review status, with a PDUFA date set for November 22, 2026.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909114-savara-stock-rare-disease-funnel-is-becoming-a-commercial-asset"},"author":{"@type":"Person","name":"Equity…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
